126 related articles for article (PubMed ID: 7535070)
1. Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival.
Gisselbrecht C
Eur J Cancer; 1994; 30A Suppl 3():S30-3. PubMed ID: 7535070
[TBL] [Abstract][Full Text] [Related]
2. Future strategy for cancer treatment using recombinant human granulocyte colony stimulating factor.
Diehl V
Eur J Cancer; 1994; 30A Suppl 3():S44-7. PubMed ID: 7535072
[TBL] [Abstract][Full Text] [Related]
3. Contribution of glycosylated recombinant human granulocyte colony-stimulating factor (lenograstim) use in current cancer treatment: review of clinical data.
Gunzer K; Clarisse B; Lheureux S; Delcambre C; Joly F
Expert Opin Biol Ther; 2010 Apr; 10(4):615-30. PubMed ID: 20218922
[TBL] [Abstract][Full Text] [Related]
4. Relevance of high-dose chemotherapy in solid tumours.
Nieboer P; de Vries EG; Mulder NH; van der Graaf WT
Cancer Treat Rev; 2005 May; 31(3):210-25. PubMed ID: 15944050
[TBL] [Abstract][Full Text] [Related]
5. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in "extensive disease" stage.
Heigener DF; Manegold C; Jäger E; Saal JG; Zuna I; Gatzemeier U
Am J Clin Oncol; 2009 Feb; 32(1):61-4. PubMed ID: 19194127
[TBL] [Abstract][Full Text] [Related]
6. Low-dose lenograstim is as effective as standard dose in shortening neutrophil engraftment time following myeloablative chemotherapy and peripheral blood progenitor cell rescue.
Nolan L; Lorigan P; Chilton S; Newman J; Else R; Smith P; Linch D; Sweetenham JW; Johnson PW
Br J Haematol; 2007 Jun; 137(5):436-42. PubMed ID: 17433027
[TBL] [Abstract][Full Text] [Related]
7. Dose intensity in small cell lung cancer.
Thatcher N; Lee SM; Woll PJ; Middleton M; Anderson H; Burt P; Stout R
Semin Oncol; 1998 Apr; 25(2 Suppl 4):12-8; discussion 45-8. PubMed ID: 9578057
[TBL] [Abstract][Full Text] [Related]
8. A threefold dose intensity treatment with ifosfamide, carboplatin, and etoposide for patients with small cell lung cancer: a randomized trial.
Leyvraz S; Pampallona S; Martinelli G; Ploner F; Perey L; Aversa S; Peters S; Brunsvig P; Montes A; Lange A; Yilmaz U; Rosti G;
J Natl Cancer Inst; 2008 Apr; 100(8):533-41. PubMed ID: 18398095
[TBL] [Abstract][Full Text] [Related]
9. Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study.
Ardizzoni A; Favaretto A; Boni L; Baldini E; Castiglioni F; Antonelli P; Pari F; Tibaldi C; Altieri AM; Barbera S; Cacciani G; Raimondi M; Tixi L; Stefani M; Monfardini S; Antilli A; Rosso R; Paccagnella A
J Clin Oncol; 2005 Jan; 23(3):569-75. PubMed ID: 15659503
[TBL] [Abstract][Full Text] [Related]
10. [Studies with high-dose chemotherapy and subsequent autologous stem cell transplantation in breast carcinoma].
Nitz U; Adomeit A; Mohrmann S; Fossari A; Frick M
Praxis (Bern 1994); 1998 Apr; 87(17):578-83. PubMed ID: 9623324
[TBL] [Abstract][Full Text] [Related]
11. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
12. The emergence of peripheral blood progenitor cells to support intensive chemotherapy for patients with breast cancer.
Demetri GD
Pharmacotherapy; 1996; 16(3 Pt 2):94S-100S. PubMed ID: 8726588
[TBL] [Abstract][Full Text] [Related]
13. Lenograstim. A review of its pharmacological properties and therapeutic efficacy in neutropenia and related clinical settings.
Frampton JE; Yarker YE; Goa KL
Drugs; 1995 May; 49(5):767-93. PubMed ID: 7541335
[TBL] [Abstract][Full Text] [Related]
14. The changing face of stem cell transplantation by the use of recombinant human granulocyte colony stimulating factor.
Boogaerts MA; Demuynck H
Eur J Cancer; 1994; 30A Suppl 3():S34-9. PubMed ID: 7535071
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
17. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
Ariyoshi Y; Ogawa M
Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
[TBL] [Abstract][Full Text] [Related]
18. [Dose intensity of chemotherapy in small-cell lung carcinoma. Review of comparative studies].
Sanz Rubiales A; del Valle Rivero ML; Garavís Vicente M; Rey Castro P; López-Lara Martín F
An Med Interna; 2000 Jul; 17(7):378-85. PubMed ID: 10981338
[TBL] [Abstract][Full Text] [Related]
19. The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy.
Crawford J; George M
Semin Oncol; 1995 Jun; 22(3 Suppl 7):18-22. PubMed ID: 7541916
[TBL] [Abstract][Full Text] [Related]
20. Increasing chemotherapy in small-cell lung cancer: from dose intensity and density to megadoses.
Crivellari G; Monfardini S; Stragliotto S; Marino D; Aversa SM
Oncologist; 2007 Jan; 12(1):79-89. PubMed ID: 17227903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
